Powerful cancer pain drugs were given to patients with other conditions who cannot tolerate them. A program to curb the practice was run by companies that sell the drugs. By Emily Baumgaertner The ...

Cephalon Inc. on Wednesday confirmed it is suing generic drug developer Watson Pharmaceuticals Inc. over that company's plan to make a generic version of Cephalon's sleep disorder drug Nuvigil.

NEW YORK, Dec 8 (Reuters) - Cephalon Inc's experimental cancer drug Treanda appeared to be effective in patients whose non-Hodgkin's lymphoma (NHL) had progressed during or following treatment with ...

WHAT: Cephalon, Inc., (Nasdaq: CEPH) will hold a public memorial service to celebrate the life of the company's founder and late Chairman and CEO, Dr. Frank Baldino, Jr. WHEN: Tuesday, February 1, ...

On the heels of the FDA nod for Genzyme Corp.'s Campath for first-line use in chronic B-cell lymphocytic leukemia, Cephalon Inc. submitted its new drug application for the orphan drug Treanda, which ...

TORONTO (Reuters) - Valeant Pharmaceuticals International Inc is expected to turn its attention to other acquisition targets in the specialty pharmaceuticals landscape after pulling out of the race to ...

U.S. drug regulators on Wednesday issued a public health advisory warning of the potential for a deadly overdose of a pain drug for cancer patients made by Cephalon Inc. The U.S. Food and Drug ...

Cephalon Inc. reacquired rights to its cancer pain product, Actiq, in 12 countries from Elan Pharma Ltd., a subsidiary of Elan Corp. plc, to the tune of $50 million in cash. Actiq is one of three ...

Cephalon, Inc. (CEPH) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion, Kevin Buchi, Chief Executive Officer of Cephalon, Inc. (CEPH), will ring the Opening ...

NEW YORK (MarketWatch) -- Mylan Laboratories Inc. said it inked a deal to allow Cephalon Inc. to use its transdermal technology in two separate agreements aimed at treatments for pain and nervous ...

Acusphere Inc. has announced that it has signed an agreement to license the intellectual property rights to its Hydrophobic Drug Delivery System™ (HDDS) for oncology applications, along with the ...